Letters to the editor [2]
dc.contributor.author | Boffard K.D. | |
dc.contributor.author | Choong P.I.T. | |
dc.contributor.author | Kluger Y. | |
dc.contributor.author | Riou B. | |
dc.contributor.author | Rizoli S. | |
dc.contributor.author | Rossaint R. | |
dc.contributor.author | Warren B. | |
dc.date.accessioned | 2011-05-15T16:17:11Z | |
dc.date.available | 2011-05-15T16:17:11Z | |
dc.date.issued | 2006 | |
dc.description.abstract | [No abstract available] | |
dc.description.version | Letter | |
dc.identifier.citation | Journal of Trauma - Injury, Infection and Critical Care | |
dc.identifier.citation | 60 | |
dc.identifier.citation | 1 | |
dc.identifier.issn | 00225282 | |
dc.identifier.other | 10.1097/01.ta.0000197375.34928.87 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/14108 | |
dc.subject | placebo | |
dc.subject | recombinant blood clotting factor 7a | |
dc.subject | bleeding | |
dc.subject | blood transfusion | |
dc.subject | blunt trauma | |
dc.subject | cause of death | |
dc.subject | clinical trial | |
dc.subject | controlled clinical trial | |
dc.subject | controlled study | |
dc.subject | drug efficacy | |
dc.subject | drug industry | |
dc.subject | drug marketing | |
dc.subject | drug safety | |
dc.subject | health care quality | |
dc.subject | human | |
dc.subject | injury severity | |
dc.subject | letter | |
dc.subject | outcome assessment | |
dc.subject | penetrating trauma | |
dc.subject | phase 2 clinical trial | |
dc.subject | priority journal | |
dc.subject | randomized controlled trial | |
dc.subject | treatment indication | |
dc.title | Letters to the editor [2] | |
dc.type | Letter |